![]() With more and more compounds derived from FBDD entering different stages of clinical studies, this method has been highly recognized in drug discovery. ![]() Several drugs such as vemurafenib-an inhibitor of oncogenic B-RAF kinase activity derived from fragment-based approach have been approved by FDA ( Erlanson, 2012). With the development of new approaches in screening and progress made in structural biology, FBDD has been readily carried on and playing important roles in target-based drug discovery ( Bollag et al., 2010, 2012 Harner et al., 2013). These advantages have encouraged researchers to adopt this method to develop inhibitors of different types of targets. Although FBDD cannot replace high-throughput screening (HTS) campaigns in drug discovery, it has some attractive advantages such as saving experimental cost, offering diverse hits, and exhibiting multiple ways to develop novel compounds ( Erlanson et al., 2016). The identified hit is then grown into drug-like molecules through different strategies. ![]() These starting hits are usually identified from a compound library using sensitive biophysical methods. FBDD usually generates a compound starting from a chemical fragment with a low binding affinity to the target, low complexity in chemical structures and low molecular weight (less than 300 Da) ( Murray and Rees, 2009 Doak et al., 2016). As FBDD can be readily carried out through different biophysical and computer-based methods, it will play more important roles in drug discovery.įragment-based drug design (FBDD) is an approach to develop potent compounds from fragments. This review elucidates fragment libraries, methods utilized in fragment identification/confirmation, strategies applied in growing the identified fragments into drug-like lead compounds, and applications of FBDD to different targets. Methods used in fragment screening and understanding fragment-binding modes are critical in FBDD. Many potent compounds/inhibitors of diverse targets have been developed using this approach. As FBDD exhibits several advantages over high-throughput screening campaigns, it becomes an attractive strategy in target-based drug discovery. Guangdong Provincial Engineering Laboratory of Biomass High Value Utilization, Guangdong Provincial Bioengineering Institute, Guangzhou Sugarcane Industry Research Institute, Guangdong Academy of Sciences, Guangzhou, Chinaįragment-based drug discovery (FBDD) is a powerful method to develop potent small-molecule compounds starting from fragments binding weakly to targets.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |